The Board of Directors of Welcure Drugs & Pharmaceuticals Ltd responded to Telexcell Trade PTE LTD's LOI for a 25% equity stake. Telexcell proposed ₹ 20 per share, nearly double the ₹ 10 market price. The Board welcomed the premium valuation but ensured management independence is non-negotiable. The Singapore-based firm must acquire the stake via secondary market routes.